Nuvation Bio Inc. filings document the regulatory record of a public oncology company with Class A common stock listed on the New York Stock Exchange. The company's 8-K disclosures cover operating and financial results, material agreements, clinical and regulatory updates for taletrectinib and safusidenib, pipeline decisions involving its drug-drug conjugate program, and other material-event disclosures.
Proxy materials describe board elections, auditor ratification, executive compensation votes, shareholder voting procedures, and governance matters. Capital-structure filings identify the company's registered securities, including Class A common stock and historical warrant-related disclosures, while Form 25 records document removal of a warrant class from exchange listing and registration.
Nuvation Bio Inc. chief regulatory officer Kerry Wentworth exercised stock options and sold shares in the company. Wentworth exercised options to acquire 63,000 shares of Class A common stock at an exercise price of $2.93 per share, then sold 63,000 shares in an open-market transaction at a weighted-average price of $6.0189 per share. The sales were made under a pre-arranged Rule 10b5-1 trading plan dated December 4, 2025. Following these transactions, Wentworth directly holds 53,000 shares of Class A common stock.
Nuvation Bio Inc. Chief Financial Officer Philippe Sauvage exercised stock options and sold shares in a coordinated transaction. He exercised options to acquire 47,668 shares of Class A common stock at $2.17 per share, then sold 47,668 shares in open-market trades at a weighted-average price of $6.0076 per share under a Rule 10b5-1 trading plan dated December 4, 2025. Following these transactions, he directly holds 12,673 shares of Class A common stock.
NUVB trading reported via a Form 144: 63,000 shares of Common stock are listed to be sold on 06/23/2026 following an exercise of stock options for cash. The filing also records prior 10b5-1 sales of 36,750 shares on 04/17/2026 and 200,000 shares on 04/06/2026.
Nuvation Bio Inc. director Robert Mashal, through the Robert D. Mashal 2020 Revocable Trust for which he is sole trustee, made an open-market purchase of 25,000 shares of Class A Common Stock at $4.73 per share. After this indirect transaction by the trust, total holdings reported for this trust-related position increased to 225,000 shares of Nuvation Bio Class A Common Stock.
Nuvation Bio Inc. reported the results of its 2026 Annual Meeting of Stockholders. Holders of 389,931,796 shares were present in person or by proxy, representing 83.6% of the Class A Common Stock and 100% of the Class B Common Stock outstanding as of March 25, 2026, which constituted a quorum.
Stockholders elected Class A directors Robert B. Bazemore, Jr. and Robert Mashal, M.D., and Class B director Kim Blickenstaff to serve until the 2029 annual meeting and until their successors are elected and qualified. Stockholders also ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
On an advisory basis, stockholders approved the compensation of the Company’s named executive officers as disclosed in the April 10, 2026 proxy statement. All three proposals received sufficient votes for approval.
Nuvation Bio Inc. director Vernon W. Anthony received a grant of stock options covering 123,397 shares of Class A common stock. The options have an exercise price of $4.79 per share and expire on May 20, 2036. All 123,397 shares subject to the option will vest on the earlier of May 21, 2026 or the next shareholder annual meeting, provided he remains in continuous service through that date. Following this compensation-related award, he holds 123,397 options directly, and the filing does not report any open-market buying or selling.
Nuvation Bio Inc. director Robert Mashal received a grant of stock options covering 123,397 shares of Class A common stock at an exercise price of $4.79 per share. These options vest 100% on the earlier of May 21, 2026 or the next shareholder annual meeting, contingent on his continuous service. Following the grant, he holds options for 123,397 shares directly, expiring on May 20, 2036.
Nuvation Bio Inc. director Kathryn E. Falberg received a grant of stock options covering 123,397 shares of Class A common stock at an exercise price of $4.79 per share. The options vest 100% on the earlier of May 21, 2026 or the next shareholder annual meeting, subject to her continuous service, and expire on May 20, 2036. Following this award, she holds 123,397 derivative securities directly.